Evidence map›Paper›PMID 29890952›Full record

ArticleBMC genomics2018

Modifier locus mapping of a transgenic F2 mouse population identifies CCDC115 as a novel aggressive prostate cancer modifier gene in humans.

Jean M Winter, Natasha L Curry, Derek M Gildea, Kendra A Williams, Minnkyong Lee, Ying Hu, Nigel P S Crawford

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. E3 ubiquitin ligases in nasopharyngeal carcinoma and implications for therapies.Journal of molecular medicine (Berlin, Germany) · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Pseudophosphatases as Regulators of MAPK Signaling.International journal of molecular sciences · 2021
    Review
  8. The Roles of Pseudophosphatases in Disease.International journal of molecular sciences · 2021
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Jean M WinterMetastasis Genetics Section, Genetics and Molecular Biology Branch, National Human Genome Research Institute, NIH, Bethesda, MD, 20892, USA.
Natasha L CurryMetastasis Genetics Section, Genetics and Molecular Biology Branch, National Human Genome Research Institute, NIH, Bethesda, MD, 20892, USA.
Derek M GildeaComputational and Statistical Genomics Branch, National Human Genome Research Institute, NIH, Bethesda, MD, 20892, USA.
Kendra A WilliamsMetastasis Genetics Section, Genetics and Molecular Biology Branch, National Human Genome Research Institute, NIH, Bethesda, MD, 20892, USA.
Minnkyong LeeMetastasis Genetics Section, Genetics and Molecular Biology Branch, National Human Genome Research Institute, NIH, Bethesda, MD, 20892, USA.
Ying HuCenter for Biomedical Informatics and Information Technology, National Cancer Institute, NIH, Rockville, MD, 20892, USA.
Nigel P S CrawfordMetastasis Genetics Section, Genetics and Molecular Biology Branch, National Human Genome Research Institute, NIH, Bethesda, MD, 20892, USA. nigel.crawford@sanofi.com.
National Human Genome Research Institute · USNational Cancer Institute · USSanofi (United States) · US

Funding

Germline modifiers of tumor progression and metastasis in prostate cancerZIAHG200366 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI CRAWFORD, NIGEL · 2010 to 2016
$5.0M
Intramural Research Program National Human Genome Research Institute (US) HG200366-05
6 · The paper itself

Abstract

backgroundIt is well known that development of prostate cancer (PC) can be attributed to somatic mutations of the genome, acquired within proto-oncogenes or tumor-suppressor genes. What is less well understood is how germline variation contributes to disease aggressiveness in PC patients. To map germline modifiers of aggressive neuroendocrine PC, we generated a genetically diverse F2 intercross population using the transgenic TRAMP mouse model and the wild-derived WSB/EiJ (WSB) strain. The relevance of germline modifiers of aggressive PC identified in these mice was extensively correlated in human PC datasets and functionally validated in cell lines.

resultsAggressive PC traits were quantified in a population of 30 week old (TRAMP x WSB) F2 mice (n = 307). Correlation of germline genotype with aggressive disease phenotype revealed seven modifier loci that were significantly associated with aggressive disease. RNA-seq were analyzed using cis-eQTL and trait correlation analyses to identify candidate genes within each of these loci. Analysis of 92 (TRAMP x WSB) F2 prostates revealed 25 candidate genes that harbored both a significant cis-eQTL and mRNA expression correlations with an aggressive PC trait. We further delineated these candidate genes based on their clinical relevance, by interrogating human PC GWAS and PC tumor gene expression datasets. We identified four genes (CCDC115, DNAJC10, RNF149, and STYXL1), which encompassed all of the following characteristics: 1) one or more germline variants associated with aggressive PC traits; 2) differential mRNA levels associated with aggressive PC traits; and 3) differential mRNA expression between normal and tumor tissue. Functional validation studies of these four genes using the human LNCaP prostate adenocarcinoma cell line revealed ectopic overexpression of CCDC115 can significantly impede cell growth in vitro and tumor growth in vivo. Furthermore, CCDC115 human prostate tumor expression was associated with better survival outcomes.

conclusionWe have demonstrated how modifier locus mapping in mouse models of PC, coupled with in silico analyses of human PC datasets, can reveal novel germline modifier genes of aggressive PC. We have also characterized CCDC115 as being associated with less aggressive PC in humans, placing it as a potential prognostic marker of aggressive PC.

Indexed as

AnimalsCell Line, TumorChromosome MappingCrosses, GeneticGene Expression ProfilingGenes, NeoplasmGenetic LociGenome-Wide Association StudyHumansMaleMiceMice, TransgenicNerve Tissue ProteinsPolymorphism, Single NucleotideProstatic NeoplasmsQuantitative Trait LociCcdc115 protein, humanNerve Tissue ProteinsRNA, MessengerCCDC115DNAJC10Germline variationLNCaPProstate cancerQuantitative trait lociRNF149STYXL1TRAMP mouse model

Identifiers

PMID29890952
PMCPMC5996485
OpenAlexW2808058793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.